Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 33 for:    eliana
Previous Study | Return to List | Next Study

Determine Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell ALL and High Risk B-cell ALL at First Relapse. Determine Feasibility and Safety of CTL019 Therapy in Pediatric Patients With High Risk B-cell ALL That Relapsed < 6 Months Post All-HSCT. (ELIANA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02435849
Recruitment Status : Active, not recruiting
First Posted : May 6, 2015
Last Update Posted : June 30, 2021
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : November 28, 2022
Estimated Study Completion Date : November 28, 2022
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):